By IANS,
Mumbai : Pharma major Lupin Ltd announced Wednesday that its Japanese subsidiary Kyowa Pharmaceutical Industry Ltd (Kyowa) has received approvals for 10 products from Japan’s Ministry of Health and Labour Welfare (MHLW).
The company said that it expects to launch these products by July 2008.
According to an official communiqué, Kyowa’s expanded product basket will now have a combined market size, as per Intercontinental Marketing Services (IMS), valued at $2.65 billion.
Giving details about the approved medicines, the release stated that Kyowa plans to aggressively market drug Amlodipine, which as per IMS data recorded sales touching $1.84 billion in Japan.
The company, in order to garner a dominating market share in this segment, is contemplating to out-licence this product to two other generic partners in Japan.
In the case of Risperidone, the company said that Kyowa at present already holds the second largest generic player.
Lupin acquired Kyowa in October 2007, and with the fresh approvals it expects to strengthen its position in the world’s second largest pharmaceutical market.